Historical outcomes for patients with stage IA NLPHL: Global NLPHL One Working Group retrospective analyses

作者：Jamie E. Flerlage, Dennis A. Eichenauer, Michael Fuchs, Sylvia Hartmann, Hans Theodor Eich, Kerry J. Savage, Andrea Lo, Brian Skinnider, Saad Akhtar, M. Shahzad Rauf, Irfan Maghfoor, Chelsea C. Pinnix, R. Steiner, Sarah A. Milgrom, Francisco Vega, Mohammed Alomari, Xiaoyin Zhang, Graham P. Collins, Ranjana H Advani, Priyadarshini Kumar, Michael Dickinson, Andrew Wirth, Richard Tsang, Anca Prica, Ajay Major, SD Smith, Peter G. Hendrickson, Chris R. Kelsey, David Hopkins, Pamela McKay, Andrea K. Ng, Julie L. Koenig, Louis S. Constine, Carla Casulo, Gukan Sakthivel, Jonathan A Baron, John P. Plastaras, Kenneth B. Roberts, Sarah Gao, Jalila Alkendi, Nasser Al Rahbi, Alexander George Balogh, Mario Levis, Umberto Ricardi, Akshay Sridhar, Pallawi Torka, Lena Specht, Ravi De Silva, Nimish Shah, Keir Pickard, Wendy Osborne, Lindsay Blazin, Michael Henry, Isabela Chang, Christine Moore Smith, Daniel Halperin, Fiona Miall, Jessica L. Brady, G. Mikhaeel, Bernadette Brennan, Anthony Penn, Mariia Senchenko, Egor Volchkov, Marie Reeves, Bradford S. Hoppe, Stephanie A Terezakis, Dipti Talaulikar, R Della Pepa, Marco Picardi, Youlia Kirova, Paige Fergusson, Michael Northend, Eliza A. Hawkes, Denise Lee, Nicole Wong Doo, Allison Barraclough, Stephen Opat, Chan Y. Cheah, Ross Salvaris, Matthew Ku, Nada Hamad, Howard Mutsando, Aditya Tedjaseputra, Michael Gilbertson, Tamara Marconi, Nicholas Viiala, Monica Palese, Ananth G Shankar, Matthew J Maurer, Yasodha Natkunam, Kara M Kelly, P Borchmann, Richard T. Hoppe, Michael S. Binkley · 发表于：Blood Advances · 年份：2026 · DOI：10.1182/bloodadvances.2026020012 · 被引用次数：1 · 研究领域：Lymphoma Diagnosis and Treatment、Viral-associated cancers and disorders、Chronic Lymphocytic Leukemia Research

ABSTRACT: We evaluated outcomes by management type for patients with stage IA nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) in the Global NLPHL One Working Group retrospective database of 2243 patients with stages I to IV disease diagnosed from 1992 to 2021 at 38 international institutions. A total of 779 patients had stage IA disease with median age of 35 years (range, 3-89) and median follow-up of 6.1 years. The 6-year progression-free survival (PFS) and overall survival were 86.3% and 97.7%, respectively. Outcomes were analyzed for the 2 groups: complete resection and unresected disease. Patients with a complete resection and observation alone (n = 99) had a 6-year PFS of 65.5% vs 90.5% for those who received radiotherapy (RT) (n = 53). Patients with unresected disease (n = 627; 80.5%) had a 6-year PFS of 62.0% for rituximab alone (n = 31), 89.6% for RT alone (n = 325), 76.8% for ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) alone (n = 40), and 94.3% for ABVD plus RT (n = 130). A total of 127 patients relapsed (16.3%), of which 25 (19.7%) had transformation. Our analysis suggests the following: (1) RT improves the PFS in patients with completely resected disease; (2) rituximab or ABVD alone does not appear to achieve a durable response; and (3) chemotherapy was not observed to add additional PFS benefit when used in combination with RT. Thus, for stage IA NLPHL, RT alone is likely sufficient for definitive treatment.